1. Home
  2. VHC vs EQ Comparison

VHC vs EQ Comparison

Compare VHC & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirnetX Holding Corp

VHC

VirnetX Holding Corp

HOLD

Current Price

$19.08

Market Cap

79.2M

Sector

Miscellaneous

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.61

Market Cap

64.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VHC
EQ
Founded
2005
2017
Country
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
64.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VHC
EQ
Price
$19.08
$1.61
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
16.3K
498.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.60
$0.27
52 Week High
$29.00
$2.35

Technical Indicators

Market Signals
Indicator
VHC
EQ
Relative Strength Index (RSI) 48.89 65.07
Support Level $17.56 $1.53
Resistance Level $21.32 $1.69
Average True Range (ATR) 1.45 0.11
MACD -0.07 0.01
Stochastic Oscillator 50.11 78.21

Price Performance

Historical Comparison
VHC
EQ

About VHC VirnetX Holding Corp

VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: